CBLL
CBLLHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CBLL focuses on Medical Devices services and products. CBLL operates as a medical technology company in the United States. With a market capitalization of $664.0M, it sits in small-cap territory. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
Market Cap
$664.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-15.93
EPS (TTM)
$-1.62
EPS (Fwd)
$-1.10
ROE
-37.5%
ROA
-20.7%
Cash
$141.2M
Total Debt
$22.1M
Free CF
-$29.3M
52W Change
2.1%
Annual Financials
Cash vs Debt
CBLL holds $141.2M in cash against $22.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$29.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.9M (2022) to $89.1M (2025), reflecting a 244% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CBLL and its sector.